NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Forecast, Price & News 0.28 +0.01 (+2.56%) (As of 12:30 PM ET) Add Compare Share Share Today's Range0.27▼0.2850-Day Range N/A52-Week Range0.21▼0.73Volume44,859 shsAverage Volume661,620 shsMarket Capitalization$77.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsHeadlinesShort InterestSocial MediaProfileChartCompetitorsEarningsHeadlinesShort InterestSocial Media About Perspective Therapeutics (NYSEAMERICAN:CATX) StockPerspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.Read More CATX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesSeptember 12, 2023 | finance.yahoo.comPerspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear MedicineAugust 30, 2023 | finance.yahoo.comPerspective Therapeutics to Present at the World Molecular Imaging Congress 2023September 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. August 28, 2023 | finance.yahoo.comPerspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear MedicineAugust 11, 2023 | finanznachrichten.dePerspective Therapeutics, Inc.: Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business HighlightsAugust 11, 2023 | finance.yahoo.comPerspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business HighlightsAugust 11, 2023 | finance.yahoo.comPerspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic MelanomaAugust 11, 2023 | finance.yahoo.comPerspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue EstimatesSeptember 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. August 9, 2023 | finance.yahoo.comPerspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer TreatmentJuly 23, 2023 | finance.yahoo.comCATX - Perspective Therapeutics, Inc.June 27, 2023 | finance.yahoo.comPerspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual ConferenceJune 16, 2023 | finance.yahoo.comPerspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual MeetingJune 8, 2023 | finance.yahoo.comPerspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging ConferenceMay 24, 2023 | finance.yahoo.comPerspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)May 19, 2023 | msn.comOppenheimer Maintains Perspective Therapeutics (CATX) Outperform RecommendationMay 16, 2023 | seekingalpha.comPerspective Therapeutics reports Q1 resultsMay 16, 2023 | finanznachrichten.dePerspective Therapeutics, Inc.: Perspective Therapeutics Reports First Quarter Fiscal 2023 ResultsMay 15, 2023 | finance.yahoo.comPerspective Therapeutics Reports First Quarter Fiscal 2023 ResultsMay 15, 2023 | finance.yahoo.comPerspective Therapeutics Announces Changes to the Board of DirectorsSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Company Calendar Last Earnings8/11/2023Today9/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CATX CUSIPN/A CIKN/A Webwww.isoray.com Phone(509) 375-1202Fax509-267-3670Employees91Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)-0.09 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,270,000.00 Net Margins-239.46% Pretax MarginN/A Return on Equity-19.46% Return on Assets-17.83% Debt Debt-to-Equity Ratio0.02 Current Ratio3.72 Quick Ratio3.59 Sales & Book Value Annual Sales$10.80 million Price / Sales7.01 Cash FlowN/A Price / Cash FlowN/A Book Value0.45 per share Price / Book0.60Miscellaneous Outstanding Shares280,570,000Free Float264,522,000Market Cap$75.75 million OptionableNot Optionable Beta1.61 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 51)CEO & Director Mr. Jonathan R. Hunt (Age 56)CFO & Co-Principal Financial Officer Comp: $144.12kMr. Shane CobbExec. VP of OperationsMr. Mark J. Austin CPA (Age 36)VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec. Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExec. VP of BrachytherapyDr. Markus Puhlmann M.B.A. (Age 57)M.D., Chief Medical Officer Mr. Amos Hedt BAPGradDip, Chief Bus. Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Sr. VP of Clinical OperationsMore ExecutivesKey CompetitorsMonogram OrthopaedicsNASDAQ:MGRMCytosorbentsNASDAQ:CTSOBeyond AirNASDAQ:XAIRSpectral MedicalOTCMKTS:EDTXFDarioHealthNASDAQ:DRIOView All Competitors CATX Stock - Frequently Asked Questions Are investors shorting Perspective Therapeutics? Perspective Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,570,000 shares, a drop of 11.8% from the August 15th total of 1,780,000 shares. Based on an average daily trading volume, of 301,900 shares, the days-to-cover ratio is presently 5.2 days. Approximately 0.8% of the shares of the company are short sold. View Perspective Therapeutics' Short Interest. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The company had revenue of $2.09 million for the quarter, compared to analyst estimates of $2.61 million. Perspective Therapeutics had a negative net margin of 239.46% and a negative trailing twelve-month return on equity of 19.46%. What is Perspective Therapeutics' stock symbol? Perspective Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CATX." What is Perspective Therapeutics' stock price today? One share of CATX stock can currently be purchased for approximately 0.27. How much money does Perspective Therapeutics make? Perspective Therapeutics (NYSEAMERICAN:CATX) has a market capitalization of $75.75 million and generates $10.80 million in revenue each year. The company earns $-7,270,000.00 in net income (profit) each year or -0.09 on an earnings per share basis. How can I contact Perspective Therapeutics? Perspective Therapeutics' mailing address is 350 HILLS STREET SUITE 106, RICHLAND WA, 99354. The official website for the company is www.isoray.com. The company can be reached via phone at (509) 375-1202, via email at dbabcock@isoray.com, or via fax at 509-267-3670. This page (NYSEAMERICAN:CATX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.